Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · December 28, 2022

Biomarkers of Disease Outcomes and Resistance Mechanisms to First-Line Osimertinib in Patients With Advanced EGFR-Mutant Lung Cancer

European Journal of Surgical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Surgical Oncology
Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers
Eur J Surg Oncol 2022 Dec 06;[EPub Ahead of Print], NJ Choudhury, A Marra, JSY Sui, J Flynn, SR Yang, CJ Falcon, P Selenica, AJ Schoenfeld, N Rekhtman, D Gomez, MF Berger, M Ladanyi, M Arcila, CM Rudin, GJ Riely, MG Kris, G Heller, JS Reis-Filho, HA Yu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading